The first studies to demonstrate this were carried out in populations with a high prevalence of CYP2A6 nonfunctional variants, but now there is good evidence that CYP2A6 genotype contributes to a smoker's lung cancer risk in a number of different populations. Here, CYP2A6 is linked to lung carcinoma.